These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 29371019)
1. Stable and sustained release liposomal formulations of celecoxib: In vitro and in vivo anti-tumor evaluation. Matbou Riahi M; Sahebkar A; Sadri K; Nikoofal-Sahlabadi S; Jaafari MR Int J Pharm; 2018 Apr; 540(1-2):89-97. PubMed ID: 29371019 [TBL] [Abstract][Full Text] [Related]
2. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib. Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998 [TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells. Limasale YD; Tezcaner A; Özen C; Keskin D; Banerjee S Int J Pharm; 2015 Feb; 479(2):364-73. PubMed ID: 25595386 [TBL] [Abstract][Full Text] [Related]
4. In-vitro characterisation of a novel celecoxib microbead formulation for the treatment and prevention of colorectal cancer. McDonald BF; Quinn AM; Devers T; Cullen A; Coulter IS; Marison IW; Loughran ST J Pharm Pharmacol; 2015 May; 67(5):685-95. PubMed ID: 25650335 [TBL] [Abstract][Full Text] [Related]
5. Formulation development of self-nanoemulsifying drug delivery system of celecoxib for the management of oral cavity inflammation. Salem HF; Kharshoum RM; Sayed OM; Abdel Hakim LF J Liposome Res; 2019 Jun; 29(2):195-205. PubMed ID: 30221598 [TBL] [Abstract][Full Text] [Related]
6. Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol-modified phospholipids. Kieler-Ferguson HM; Chan D; Sockolosky J; Finney L; Maxey E; Vogt S; Szoka FC Eur J Pharm Sci; 2017 May; 103():85-93. PubMed ID: 28263913 [TBL] [Abstract][Full Text] [Related]
7. In vitro characterization of a liposomal formulation of celecoxib containing 1,2-distearoyl-sn-glycero-3-phosphocholine, cholesterol, and polyethylene glycol and its functional effects against colorectal cancer cell lines. Erdoğ A; Putra Limasale YD; Keskin D; Tezcaner A; Banerjee S J Pharm Sci; 2013 Oct; 102(10):3666-77. PubMed ID: 23897281 [TBL] [Abstract][Full Text] [Related]
8. Regulating the Golgi apparatus by co-delivery of a COX-2 inhibitor and Brefeldin A for suppression of tumor metastasis. Yu RY; Xing L; Cui PF; Qiao JB; He YJ; Chang X; Zhou TJ; Jin QR; Jiang HL; Xiao Y Biomater Sci; 2018 Jul; 6(8):2144-2155. PubMed ID: 29923556 [TBL] [Abstract][Full Text] [Related]
9. Preparation and characterization of nanoliposomal bortezomib formulations and evaluation of their anti-cancer efficacy in mice bearing C26 colon carcinoma and B16F0 melanoma. Korani M; Ghaffari S; Attar H; Mashreghi M; Jaafari MR Nanomedicine; 2019 Aug; 20():102013. PubMed ID: 31103736 [TBL] [Abstract][Full Text] [Related]
10. Celecoxib-loaded liposomes: effect of cholesterol on encapsulation and in vitro release characteristics. Deniz A; Sade A; Severcan F; Keskin D; Tezcaner A; Banerjee S Biosci Rep; 2010 Jun; 30(5):365-73. PubMed ID: 19900165 [TBL] [Abstract][Full Text] [Related]
11. Liposome-based codelivery of celecoxib and doxorubicin hydrochloride as a synergistic dual-drug delivery system for enhancing the anticancer effect. Ahmed KS; Changling S; Shan X; Mao J; Qiu L; Chen J J Liposome Res; 2020 Sep; 30(3):285-296. PubMed ID: 31223044 [TBL] [Abstract][Full Text] [Related]
12. The impact of phospholipids with high transition temperature to enhance redox-sensitive liposomal doxorubicin efficacy in colon carcinoma model. Mirhadi E; Askarizadeh A; Farhoudi L; Mashreghi M; Behboodifar S; Alavizadeh SH; Arabi L; Jaafari MR Chem Phys Lipids; 2024 Jul; 261():105396. PubMed ID: 38621603 [TBL] [Abstract][Full Text] [Related]
13. Sterically stabilized liposomes incorporating the novel anticancer agent phospho-ibuprofen (MDC-917): preparation, characterization, and in vitro/in vivo evaluation. Mattheolabakis G; Nie T; Constantinides PP; Rigas B Pharm Res; 2012 Jun; 29(6):1435-43. PubMed ID: 22072052 [TBL] [Abstract][Full Text] [Related]
14. Formulation design and optimization of novel soft glycerosomes for enhanced topical delivery of celecoxib and cupferron by Box-Behnken statistical design. Salem HF; Kharshoum RM; Sayed OM; Abdel Hakim LF Drug Dev Ind Pharm; 2018 Nov; 44(11):1871-1884. PubMed ID: 30044654 [TBL] [Abstract][Full Text] [Related]
15. Preparation and characterization of stable nanoliposomal formulations of curcumin with high loading efficacy: In vitro and in vivo anti-tumor study. Karimi M; Gheybi F; Zamani P; Mashreghi M; Golmohammadzadeh S; Darban SA; Badiee A; Jaafari MR Int J Pharm; 2020 Apr; 580():119211. PubMed ID: 32156530 [TBL] [Abstract][Full Text] [Related]
16. Multivesicular liposomes bearing celecoxib-beta-cyclodextrin complex for transdermal delivery. Jain SK; Gupta Y; Jain A; Bhola M Drug Deliv; 2007 Aug; 14(6):327-35. PubMed ID: 17701522 [TBL] [Abstract][Full Text] [Related]
17. Preparation and in vitro evaluation of meloxicam-loaded PLGA nanoparticles on HT-29 human colon adenocarcinoma cells. Şengel-Türk CT; Hasçiçek C; Dogan AL; Esendagli G; Guc D; Gönül N Drug Dev Ind Pharm; 2012 Sep; 38(9):1107-16. PubMed ID: 22348284 [TBL] [Abstract][Full Text] [Related]
18. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity. Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937 [TBL] [Abstract][Full Text] [Related]
19. Long-Circulating Curcumin-Loaded Liposome Formulations with High Incorporation Efficiency, Stability and Anticancer Activity towards Pancreatic Adenocarcinoma Cell Lines In Vitro. Mahmud M; Piwoni A; Filipczak N; Janicka M; Gubernator J PLoS One; 2016; 11(12):e0167787. PubMed ID: 27936114 [TBL] [Abstract][Full Text] [Related]
20. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin. Abu Lila AS; Matsumoto H; Doi Y; Nakamura H; Ishida T; Kiwada H Eur J Pharm Biopharm; 2012 Aug; 81(3):524-31. PubMed ID: 22554766 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]